Alterome Therapeutics

Executive Summary

Alterome Therapeutics is a clinical-stage precision oncology company dedicated to developing first-in-class, alteration-specific therapies for cancers driven by mutant KRAS and mutant AKT E17K. Founded in 2021 and headquartered in San Diego, the company addresses critical unmet needs in aggressive cancers with limited treatment options. By targeting these challenging mutations with high specificity, Alterome aims to deliver safer and more effective therapies. The company is currently advancing its lead programs through Phase 1 clinical trials, with a focus on generating proof-of-concept data that could de-risk its pipeline and attract strategic partnerships. Despite the early stage, Alterome's focus on validated yet difficult targets positions it uniquely in the precision oncology landscape.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 dose-escalation data for lead KRAS mutant inhibitor40% success
• Q4 2026Phase 1 preliminary efficacy data for AKT E17K inhibitor35% success
• Q1 2027Pipeline update and potential new candidate nomination60% success